Hamilton Thorne (TSX:HTL) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

HTL Aktienübersicht

HTL fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	4/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Belohnungen

62.3% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 140.81% pro Jahr

Analysten sind sich einig, dass der Aktienkurs um 62%

Risikoanalyse

Die Aktionäre wurden im vergangenen Jahr verwässert

Hamilton Thorne Ltd. Wettbewerber

Opsens

TSX:OPS

CA$335.8m

Profound Medical

TSX:PRN

CA$244.3m

Nanalysis Scientific

TSXV:NSCI

CA$49.7m

Theralase Technologies

TSXV:TLT

CA$39.5m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Hamilton Thorne
Historical stock prices
Current Share Price	CA$1.42
52 Week High	CA$1.56
52 Week Low	CA$1.05
Beta	0.28
1 Month Change	2.90%
3 Month Change	10.94%
1 Year Change	-5.96%
3 Year Change	-25.26%
5 Year Change	27.93%
Change since IPO	273.68%

Aktuelle Nachrichten und Updates

Recent updates

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well

Aug 15

Announcing: Hamilton Thorne (CVE:HTL) Stock Soared An Exciting 590% In The Last Five Years

Jan 19

Are Insiders Selling Hamilton Thorne Ltd. (CVE:HTL) Stock?

Jan 06

What Did Hamilton Thorne's (CVE:HTL) CEO Take Home Last Year?

Dec 24

We Think Hamilton Thorne (CVE:HTL) Can Stay On Top Of Its Debt

Dec 12

Is It Time To Consider Buying Hamilton Thorne Ltd. (CVE:HTL)?

Nov 30

A Look At The Fair Value Of Hamilton Thorne Ltd. (CVE:HTL)

Nov 17

Here's Why Hamilton Thorne (CVE:HTL) Can Manage Its Debt Responsibly

Aug 24

Is Now An Opportune Moment To Examine Hamilton Thorne Ltd. (CVE:HTL)?

Aug 10

At CA$1.43, Is Hamilton Thorne Ltd. (CVE:HTL) Worth Looking At Closely?

Aug 10

Aktionärsrenditen

	HTL	CA Medical Equipment	CA Markt
7D	0%	-3.0%	-1.9%
1Y	-6.0%	-30.7%	12.2%

Rendite im Vergleich zur Industrie: HTL übertraf die Branche Canadian Medical Equipment, die im vergangenen Jahr eine Rendite von -27.7 erzielte.

Rendite vs. Markt: HTL hinter dem Markt Canadian zurück, der im vergangenen Jahr eine Rendite von 12.4 erzielte.

Preisvolatilität

Is HTL's price volatile compared to industry and market?
HTL volatility
HTL Average Weekly Movement	2.9%
Medical Equipment Industry Average Movement	10.6%
Market Average Movement	8.8%
10% most volatile stocks in CA Market	17.4%
10% least volatile stocks in CA Market	2.9%

Stabiler Aktienkurs: HTL hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: HTLDie wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
n/a	n/a	Kate Torchilin	www.hamiltonthorne.ltd

Hamilton Thorne Ltd. entwickelt, fertigt und vertreibt Präzisionsinstrumente, Laborgeräte, Verbrauchsmaterialien, Software und Dienstleistungen für die Märkte der assistierten Reproduktionstechnologien (ART), Forschung und Zellbiologie. Das Unternehmen bietet Präzisionslasersysteme und Bildgebungssysteme für den Biologiemarkt an. Darüber hinaus bietet es Testlabor- und Endotoxintestdienste sowie Spermatests, einschließlich Spermienmotilitätsindex und Spermienpenetration, und die Lieferung von frischen und kryokonservierten Mausembryonen sowie Technikerschulungen und Leistungstests an.

Hamilton Thorne Ltd.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Hamilton Thorne im Vergleich zum Marktanteil des Unternehmens?
HTL grundlegende Statistiken
Marktanteil	CA$218.32m
Gewinn(TTM)	-CA$2.22m
Umsatz(TTM)	CA$95.83m

2.3x

Kurs-Umsatz-Verhältnis

-98.3x

Kurs-Gewinn-Verhältnis

Ist HTL zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
HTL Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$69.93m
Kosten der Einnahmen	US$34.36m
Bruttogewinn	US$35.57m
Sonstige Ausgaben	US$37.19m
Umsatz	-US$1.62m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.011
Bruttomarge	50.87%
Nettogewinnspanne	-2.32%
Schulden/Eigenkapital-Verhältnis	33.1%

Wie hat sich HTL auf lange Sicht entwickelt?

Historische Performance und Vergleiche

HTL Aktienübersicht

Belohnungen

Risikoanalyse

Hamilton Thorne Ltd. Wettbewerber

TSX:OPS

CA$335.8m

TSX:PRN

CA$244.3m

TSXV:NSCI

CA$49.7m

TSXV:TLT

CA$39.5m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hamilton Thorne Ltd. to Report Q1, 2024 Results on May 14, 2024

Hamilton Thorne Ltd., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$0.004 loss per share (vs US$0.013 profit in FY 2022)

Hamilton Thorne Ltd. Provides Earnings Guidance for the First Quarter 2024 and Full Twelve Months of 2024

Hamilton Thorne Ltd. to Report Q4, 2023 Results on Mar 27, 2024

Recent updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hamilton Thorne Ltd. to Report Q1, 2024 Results on May 14, 2024

Hamilton Thorne Ltd., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$0.004 loss per share (vs US$0.013 profit in FY 2022)

Hamilton Thorne Ltd. Provides Earnings Guidance for the First Quarter 2024 and Full Twelve Months of 2024

Hamilton Thorne Ltd. to Report Q4, 2023 Results on Mar 27, 2024

Hamilton Thorne Ltd. Announces CEO Changes, Effective January 15, 2024

New major risk - Revenue and earnings growth

Hamilton Thorne Ltd. to Report Q3, 2023 Results on Nov 13, 2023

Hamilton Thorne Ltd. (TSX:HTL) agreed to acquire Gynetics Medical Products N.V. for an enterprise value of €18.3 million.

Consensus EPS estimates increase by 80%

New minor risk - Shareholder dilution

Hamilton Thorne Ltd.(TSXV:HTL) dropped from S&P/TSX Venture Composite Index

Consensus EPS estimates fall by 80%

Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.002 profit in 2Q 2022)

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well

Hamilton Thorne Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Consensus EPS estimates fall by 50%

First quarter 2023 earnings released: EPS: US$0.001 (vs US$0.004 in 1Q 2022)

Hamilton Thorne Ltd. to Report Q1, 2023 Results on May 15, 2023

Chair, President & CEO exercised options to buy CA$102k worth of stock.

Chair, President & CEO recently sold CA$101k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued

Consensus EPS estimates increase by 17%

Now 20% undervalued after recent price drop

Hamilton Thorne Ltd. Announces Passing of Diarmaid Douglas-Hamilton, Cofounder and Chief Technology Officer

Now 21% undervalued after recent price drop

Hamilton Thorne Ltd. (TSXV:HTL) agreed to acquire Microptic, S.L.

Consensus EPS estimates fall by 33%

Hamilton Thorne Ltd. Provides Sales Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: US$0.001 (vs US$0.002 in 3Q 2021)

High number of new directors

Hamilton Thorne Ltd. to Report Nine Months, 2022 Results on Nov 22, 2022

Consensus EPS estimates fall by 23%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Hamilton Thorne Ltd. to Report Q2, 2022 Results on Aug 23, 2022

Hamilton Thorne Ltd. Announces CFO Changes

Chair, President exercised options to buy CA$86k worth of stock.

Chair, President exercised options to buy CA$886k worth of stock.

Consensus EPS estimates fall by 20%

At CA$1.40, Is Hamilton Thorne Ltd. (CVE:HTL) Worth Looking At Closely?

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Hamilton Thorne Ltd. to Report Q1, 2022 Results on May 19, 2022

Investor sentiment deteriorated over the past week

High number of new directors

Hamilton Thorne Ltd., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Chair, President exercised options to buy CA$293k worth of stock.

Hamilton Thorne Ltd. to Report Q4, 2021 Results on Apr 07, 2022

Is Hamilton Thorne (CVE:HTL) Using Too Much Debt?

High number of new directors

President recently bought CA$75k worth of stock

President recently sold CA$635k worth of stock

Third quarter 2021 earnings: EPS and revenues miss analyst expectations

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Safely

Second quarter 2021 earnings released: EPS US$0.003 (vs US$0.004 loss in 2Q 2020)

Hamilton Thorne Ltd. (TSXV:HTL) acquired IVFTECH ApS and K4 Technology ApS for an enterprise value of approximately DKK 50 million ($8 million).

Erträge & Einnahmen